Abstract
Pediatric nasopharyngeal carcinoma is a rare malignancy strongly associated with Epstein-Barr virus infection. Patients typically present with non-specific symptoms of epistaxis or serous otitis from eustachian tube obstruction and therefore diagnosis is often delayed. We present a case of a previously healthy 17 year old female who initially complained of migraines which was resistant to oral medication. Symptoms progressed and she saw a dental surgeon for concern of a dental infection and was prescribed antibiotics with no relief. Her symptoms continued to progress until an otolaryngologist visualized a large mass along the floor of the left nasal cavity. Subsequent imaging showed a large mass in the posterior left nasal cavity and biopsy was consistent with nasopharyngeal carcinoma.
Case Presentation
We present a previously healthy 17 year old female who initially complained of migraines resistant to ibuprofen and imitrex. Symptoms progressed over the next 3–4 months to nasal congestion and she became unable to breathe through the left nostril. She saw a dental surgeon for trismus due to concern of a dental infection and was prescribed antibiotics (Amoxicillin) with no relief. Her symptoms progressed over another 3 months to unexplained weight loss, headaches, loss of hearing, frequent bloody nose, tooth pain, and hoarseness. Approximately 9 months after her initial symptoms, she eventually was seen by ENT and a rigid nasal endoscopy was performed which demonstrated a polypoid mass along the floor of the left nasal cavity. MRI with and without gadolinium contrast performed on a 3-T Siemens Skyra showed a large mass in the posterior left nasal cavity and nasopharynx invading the left maxillary sinus, nasal septum, left pterygopalatine fossa, left masticator and pharyngeal spaces and left longus colli muscle causing narrowing of the nasal airway and nasopharynx as well as a unilateral mastoid effusion (Figure 1, top row). The top differential considerations included adenoidal benign lymphoid hyperplasia, nasopharyngeal non-Hodgkin and Hodgkin lymphoma, juvenile angiofibroma, nasopharyngeal rhabdomyosarcoma, and nasopharyngeal carcinoma. Subsequent biopsy of the mass was consistent with non-keratinizing nasopharyngeal carcinoma (Figure 2). She then presented for an 18F-FDG PET/CT study performed on a Philips Gemini Time of Flight system imaged from the top of the skull to the feet (FDG dose 6.8 mCi). The scan demonstrated an intense FDG avid mass in the left nasopharynx and nasal cavity extending to the left maxillary sinus (SUV max 10.8) and a metastatic left cervical lymph node (SUV max 6.9) with no distant metastasis (Figure 1, bottom row). EBV panel and PCR were both strongly positive (see Discussion section). According to the TNM classification, the tumor was classified as T3 (tumor has grown into the sinuses and/or bones nearby), N2 (spread to nearby lymph nodes no larger than 6 cm), and M0 (no distant metastasis), stratifying her to stage III disease. She has recently completed neoadjuvant chemotherapy (cisplatin and 5-fluorouracil) and radiation therapy and currently under strict follow-up. This retrospective study was approved by the Institutional Review Board and the informed consent was obtained.
Figure 1
Figure 2
Discussion
Nasopharyngeal carcinoma (NPC) is a mucosal tumor of the lateral pharyngeal recess and is a relatively rare disease in the US with an annual incidence of 0.5–2.0 cases per 100,000. Peak incidence is 40–60 years with males being at a higher risk. NPC is a rare malignancy in children accounting for <1% of all pediatric neoplasms. They typically present at a later stage in children due to the non-specific symptoms of epistaxis, headaches, nasal congestion, and conductive hearing loss secondary to middle ear obstruction. There is a strong association of NPC with Epstein-Barr Virus (EBV) infection where it is found in 90–100% of cases (–). In our case, lab values were positive for EBV infection: EBV qPCR was 2,900 IU/mL (normal not detected), EBV Ab VCA IgM <36.0 U/mL (positive >43.9), EBV Early Antigen Ab IgG >150 U/mL (positive >10.9), EBV Ab VCA IgG >600 U/mL (positive >21.9), and EBV Nuclear Antigen Ab IgG >600 U/mL (positive >21.9). Pediatric NPC differs from adult NPC due to its advanced locoregional disease and are most often undifferentiated with a strong association with EBV.
According to the World Health Organization, there are 3 different histologic subtypes of NPC. Keratinizing squamous cell carcinoma (WHO type 1) represents about 25% of all NPCs and has a weak association with EBV and an overall 5 year survival of 20–40%. Non-keratinizing differentiated carcinoma (WHO type 2) represents about 12% of all NPCs and has a strong association with EBV and an overall 5 year survival of 65%. Non-keratinizing undifferentiated carcinoma (WHO type 3) as seen in our patient is the most common subtype accounting for >60% of all NPCs and is the most frequent pediatric subtype. It has a strong association with EBV and a 5 year survival of 73–95% (). Compared to adults, pediatric patients have a significantly greater overall and relapse-free survival (, ).
The gold standard for initial diagnosis of NPC is with nasopharyngeal endoscopy with biopsy and radiologic imaging to aid in the staging and extent of disease. CT and MRI are often performed with MRI being the preferred imaging modality (, ). T1 images typically show an asymmetric mass which is hypo to isointense to muscle and T2 images shows moderate hyperintensity. Invasion of the mass into the skull base is more readily detected on MRI due to changes of the marrow signal of the clivus (decreased on T1 and increased on T2) (). Prior to the initiation of therapy, PET/CT is often used for initial staging to assess for local and distant metastasis as in our case which demonstrated a single metastatic left cervical node. Although the MRI report noted bilateral level 2 cervical lymph nodes, PET/CT was able to localize the increased metabolic activity to a single left-sided level 2 cervical node.
Conclusion
NPC is a rare pediatric malignancy that often goes undiagnosed until a later stage. This case highlights the importance of recognizing the signs and symptoms of NPC tumors and the importance of radiographic imaging. As in our case, many of the pediatric cases of NPC tend to be diagnosed at a later stage due to the non-specific symptoms.
Statements
Author contributions
RaM wrote and edited the manuscript and captured images. FV and HG captured pathology slides and assisted with figures. RiM captured MRI images and edited the manuscript. MO assisted in writing and editing the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
PunwaneyRBrandweinMSZhangDYUrkenMLChengRParkCSet al. Human papillomavirus may be common within nasopharyngeal carcinoma of caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck. (1999) 21:21–9.
2.
González-MottaAGonzálezGBermudézYMaldonadoMCCastañedaJMLopézDet al. Pediatric nasopharyngeal cancer: case report and review of the literature. Cureus. (2016) 8:e497. 10.7759/cureus.497
3.
KamranSCRiazNLeeN. Nasopharyngeal carcinoma. Surg Oncol Clin N Am. (2015) 24:547–61. 10.1016/j.soc.2015.03.008
4.
PernickN. Nasopharyngeal Carcinoma - General. PathologyOutlines.com website. Available online at: http://www.pathologyoutlines.com/topic/nasalnasopharyngealgeneral.html (Accessed September 5, 2018).
5.
RoganovicJMatijasicNMascarinM. Pediatric advanced stage nasopharyngeal carcinoma - case report. Acta Med Acad. (2015) 44:186–90. 10.5644/ama2006-124.145
6.
NikitovicMPopovic-VukovicMStanicDBokunJParipovicLIlicVet al. Treatment outcome of childhood nasopharyngeal carcinoma: a single institution experience. Int J Pediatr Otorhinolaryngol. (2018) 113:168–72. 10.1016/j.ijporl.2018.07.031
7.
KingADVlantisACBhatiaKSZeeBCWooJKTseGMet al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology. (2011) 258:531–7. 10.1148/radiol.10101241
8.
DourtheMEBolleSTemamSJouinAClaudeLReguerreYet al. Childhood nasopharyngeal carcinoma: state-of-the-art, and questions for the future. J Pediatr Hematol Oncol. (2018) 40:85–92. 10.1097/MPH.0000000000001054
9.
StambukHEPatelSGMosierKMWoldenSLHolodnyAI. Nasopharyngeal carcinoma: recognizing the radiographic features in children. AJNR Am J Neuroradiol. (2005) 26:1575–9.
Summary
Keywords
pediatrics, nasopharyngeal carcinoma, PET/CT, FDG, Epstein-Barr virus
Citation
Muzaffar R, Vacca F, Guo H, Mhapsekar R and Osman MM (2019) Pediatric Nasopharyngeal Carcinoma as Seen on 18F-FDG PET/CT. Front. Oncol. 9:110. doi: 10.3389/fonc.2019.00110
Received
11 October 2018
Accepted
06 February 2019
Published
06 March 2019
Volume
9 - 2019
Edited by
Georgios S. Limouris, National and Kapodistrian University of Athens, Greece
Reviewed by
Athanasios Zafeirakis, Army Share Fund Hospital (NIMTS), Greece; Cigdem Soydal, Ankara University, Turkey; Reza Vali, Hospital for Sick Children, Canada
Updates
Copyright
© 2019 Muzaffar, Vacca, Guo, Mhapsekar and Osman.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Razi Muzaffar razi.muzaffar@health.slu.edu
This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.